Ashwagandha, rhodiola, and reishi are among the most commercially important botanical categories in nutraceuticals, yet turning these adaptogen extracts into consistent, bioavailable finished products remains a persistent formulation challenge. The reason: the type and ratio of bioactive compounds in an extract, not just the total percentage on the label, determines both efficacy and absorption.
The gap between extracts can be enormous. A 2025 randomized crossover study found that ashwagandha extracts rich in withanolide glycosides delivered up to 226-fold higher systemic exposure per milligram than aglycone-dominant extracts at equivalent total withanolide doses.[1] Meanwhile, a 2026 analysis of commercial rhodiola supplements found rosavin concentrations ranging from 0.01% to 3.08%, with some products falling five times below label claims.[2]
At Vitafoods Europe 2026 (May 5-7, Fira Barcelona Gran Via), ingredient suppliers showcased bioavailability enhancement platforms and low-dose, high-potency extract formats designed to address these bottlenecks. This article breaks down the standardization challenges by ingredient, examines the excipient compatibility issues formulators face, and reviews the delivery technologies presented in Barcelona.
Table of Contents
- Why Adaptogen Standardization Remains a Formulation Bottleneck
- Ashwagandha: Withanolide Type Matters More Than Total Content
- Rhodiola Rosea: Label Claims vs. Measured Reality
- Reishi: Triterpene Quantification and the Alpha-Glucan Confound
- Excipient Compatibility Challenges for Adaptogen Extracts
- Bioavailability Enhancement Technologies at Vitafoods 2026
- Low-Dose Formulations and the Vitafoods 2026 Exhibitor Landscape
- Comparison Table: Adaptogen Extract Standardization and Bioavailability
- FAQs
- Key Takeaways
- Sources
Why Adaptogen Standardization Remains a Formulation Bottleneck
Adaptogen extracts derive their biological activity from complex mixtures of secondary metabolites: withanolides in ashwagandha, rosavins and salidroside in rhodiola, and ganoderic acids and beta-glucans in reishi. These plant-derived mixtures vary in composition depending on the plant part used (root vs. leaf vs. fruiting body), geographical origin, harvest season, and extraction method.[3] The United States Pharmacopeia (USP) standardized method for testing withanolides identifies only eight to ten compounds out of dozens present in Withania somnifera.[4] Two ashwagandha extracts labeled at the same total withanolide percentage can therefore contain fundamentally different withanolide profiles with vastly different pharmacokinetic behavior in humans.
For procurement teams, “5% withanolides” or “3% rosavins” on a certificate of analysis (COA) tells an incomplete story. Without compound-level characterization, formulators cannot reliably predict how an extract will perform in a finished product or whether it will deliver the systemic exposure demonstrated in clinical studies.
Infographic on adaptogen formulation:
Ashwagandha: Withanolide Type Matters More Than Total Content
The critical distinction is between withanolide glycosides (sugar-conjugated forms such as withanoside IV) and withanolide aglycones (non-glycosylated forms such as withaferin A). Glycosides exhibit higher water solubility and more favorable absorption kinetics, while aglycones are more lipophilic with lower oral bioavailability.[1,4]
A 2025 randomized, double-blind, four-way crossover pharmacokinetic study in 16 healthy adults quantified this gap.[1] Four commercially available extracts, each delivering 185 mg total withanolides, were compared:
Table 1: Pharmacokinetic Comparison of Four Ashwagandha Extracts (185 mg Total Withanolides)
| Extract | Withanolide Type | Dose Required | AUC0-t (ng-h/mL) | Cmax (ng/mL) |
|---|---|---|---|---|
| WS-35 (35% glycosides) | Glycoside-dominant | 480 mg | 656.52 | 60.42 |
| WS-10 (10% glycosides) | Mixed | 1,800 mg | 20.81 | 5.61 |
| WS-5 (5% aglycones) | Aglycone-dominant | 3,700 mg | 22.38 | 6.34 |
| WS-2.5 (2.5% aglycones) | Aglycone-dominant | 7,400 mg | 37.79 | 10.78 |
Per milligram of extract, WS-35 demonstrated 118-fold, 226-fold, and 268-fold higher AUC0-t than WS-10, WS-5, and WS-2.5, respectively.[1]
The commercial landscape reflects this science. KSM-66 (Ixoreal Biomed, booth 3F56) is standardized to 5% withanolides from root only and carries the largest clinical portfolio. Sensoril (Natreon/Kerry) uses root-and-leaf extraction at 10% withanolide glycosides, enabling efficacy at 125 mg daily. Shoden (Arjuna Natural) concentrates to 35% withanolide glycosides for ultra-low-dose applications at 60 mg daily.[4] Ashwa.30 (Natural Remedies) won the Vitafoods Europe 2026 Innovation Award in sports nutrition, delivering clinical benefits at 30 mg daily with a 44% reduction in DASS-21 stress scores and a 10% increase in VO2 max.[5]
Rhodiola Rosea: Label Claims vs. Measured Reality
Rhodiola extracts are conventionally standardized to 3% rosavins and 1% salidroside, reflecting the natural ratio found in high-quality roots and the concentrations used in the original clinical studies. The 3:1 rosavin-to-salidroside ratio is not arbitrary: salidroside modulates the hypothalamic-pituitary-adrenal (HPA) axis stress response, while rosavins contribute to monoamine oxidase (MAO) inhibition, and the clinical evidence base was built on extracts maintaining this specific balance.[6] A 2026 study published in PLOS ONE by researchers at the University of California, Irvine analyzed ten commercial rhodiola supplements using reversed-phase ultra-performance liquid chromatography (UPLC) and found substantial quality inconsistencies.[2]
Rosavin concentrations ranged from 0.01% to 3.08%, and salidroside from 0.07% to 2.91%. One capsule product labeled at 1% rosavins contained levels nearly five times lower than declared. All seven capsule products contained trace arsenic, cobalt, and lead, with one product showing arsenic and cobalt concentrations 6.5-fold and 14-fold above the median.[2]
At Vitafoods 2026, Nektium (booth UWA10) showcased Rhodiolife, a 100% identity-guaranteed Rhodiola rosea extract standardized to defined grades of rosavins and salidroside, alongside clinical data showing combined rhodiola-caffeine supplementation enhances explosive power and sustained output.[7]
Reishi: Triterpene Quantification and the Alpha-Glucan Confound
Reishi (Ganoderma lucidum) standardization faces a dual analytical challenge. Over 150 triterpenoid compounds (ganoderic acids) have been identified in reishi, and these compounds drive the immunomodulatory and hepatoprotective activities most relevant to supplement formulators.[8] However, standard colorimetric assays for total triterpene content overestimate bioactive levels because fatty acids present in the extract react positively in the assay, inflating measured values beyond the actual triterpenoid concentration.[8]
The second challenge mirrors the problem identified across the broader mushroom ingredient sector: conventional beta-glucan testing methods fail to distinguish bioactive fungal beta-1,3/1,6 glucans from starch-derived alpha-glucans in mycelium-on-grain products. Products grown on grain substrates may show high total polysaccharide numbers driven by grain starch rather than fungal bioactive compounds.[9] Formulators should request COAs that separately quantify alpha-glucan content using the Megazyme K-YBGL enzymatic method alongside HPLC-based ganoderic acid quantification, and confirm that dual-extraction methods (hot water for polysaccharides, ethanol for triterpenoids) were used.[8,9]
Have a look at our article on Functional Mushrooms at Vitafoods 2026:
Excipient Compatibility Challenges for Adaptogen Extracts
Withanolides are sensitive to hydrolysis and oxidation. Stability studies on standardized ashwagandha extracts show significant declines in withaferin A and withanolide A under both real-time (25 degrees C, 60% relative humidity) and accelerated storage conditions, with moisture sensitivity above 10% identified as the primary instability trigger and pH 7 as the most stable microenvironment.[10]
Excipient selection directly affects retention of actives. Magnesium stearate raises the local pH microenvironment and can accelerate hydrolysis of pH-sensitive compounds.[11] Ethyl cellulose showed maximum drug content retention and minimum interaction with withanolides, while hydroxypropyl cellulose demonstrated the highest interaction.[10] Expanding adaptogen delivery into gummies and beverages introduces further challenges. Gummy matrices require precise control of water activity, and even minor fluctuations in moisture content or pH can alter the degradation kinetics of sensitive withanolides and rosavins. Reishi’s pronounced bitterness, driven by ganoderic acid content, demands effective taste-masking excipients for any consumer-facing format. Rhodiola’s astringent flavor profile limits its compatibility with many beverage bases without significant reformulation. Oxidation-sensitive adaptogen actives also require packaging solutions that manage both humidity and oxygen exposure throughout shelf life.
Bioavailability Enhancement Technologies at Vitafoods 2026
Several delivery platforms addressing the low oral bioavailability of adaptogen actives were showcased in Barcelona.
Phytosome technology (Indena, booth 3B104) complexes actives with phosphatidylcholine for improved intestinal membrane crossing. Indena has applied this to curcumin, quercetin (Quercefit), and CoQ10 (Ubiqsome), and the platform is technically applicable to lipophilic withanolide aglycones and ganoderic acids.[12]
Dual-coating cyclodextrin-phospholipid technology was presented by Evanium, a German startup and Vitafoods 2026 Start-Up Challenge finalist. Evanium’s Optisolv platform combines an inner cyclodextrin core (forming water-soluble inclusion complexes) with an outer phospholipid shell (enhancing intestinal permeability), stabilizing actives in a crystal-free, dispersible state using all-natural excipient components.[13]
Cyclodextrin-based nanofiber systems represent an emerging academic approach: a 2025 study demonstrated electrospun cyclodextrin/polyvinylpyrrolidone (PVP) nanofibers significantly improved dissolution and permeability of salidroside and rosarin from Rhodiola rosea extract compared to crude extract.[14]
Microencapsulation (Lubrizol, booth 5B12) was shown in sugar-free gummy format with enhanced bioavailability, stability, and taste masking.[15]
Low-Dose Formulations and the Vitafoods 2026 Exhibitor Landscape
A defining trend at Vitafoods 2026 was the movement toward lower daily doses enabled by higher-potency extracts and enhanced delivery systems. This shift is driven by consumer preference for smaller, more convenient dosage forms; the pharmacokinetic evidence that extract composition determines systemic exposure more than dose volume; and commercial pressure to reduce cost-per-serving. Ashwa.30 delivers clinical benefits at 30 mg, Shoden at 60 mg, and Sensoril at 125 mg, compared to the 300-600 mg typical of root-only 5% extracts.[4,5] These low-dose formats open adaptogen delivery to gummies (limited to approximately 200-500 mg active payload), dissolving strips, and functional beverages where high milligram doses were previously impractical. Laboratoire PYC showcased mindful adaptogen beverage platforms incorporating standardized extracts of ashwagandha, lion’s mane, rhodiola, and chaga in vegan mushroom-based blends.[16] Sabinsa Europe (booth 3F104) exhibited its vertically integrated adaptogen portfolio, and Indena demonstrated the breadth of its Phytosome platform across multiple botanical actives.[12]
Formulators evaluating enhanced-delivery adaptogens should note the regulatory dimension: in the EU, novel delivery technologies may trigger novel food authorization under Regulation (EU) 2015/2283. In the U.S., substantially different ingredient forms may require a New Dietary Ingredient (NDI) notification to the FDA.[17]
Comparison Table: Adaptogen Extract Standardization and Bioavailability
Table 2: Standardization and Bioavailability of Major Branded Adaptogen Extracts at Vitafoods 2026
| Extract | Species | Standardization | Plant Part | Clinical Dose (mg/day) | Bioavailability Approach |
|---|---|---|---|---|---|
| KSM-66 | W. somnifera | 5% withanolides | Root only | 300-600 | Unenhanced |
| Sensoril | W. somnifera | 10% withanolide glycosides | Root + leaf | 125-250 | Glycoside enrichment |
| Shoden | W. somnifera | 35% withanolide glycosides | Root + leaf | 60-120 | Glycoside concentration |
| Ashwa.30 | W. somnifera | 30% Bio-Active Complex | Root only | 30 | ATP-active fractions |
| Rhodiolife | R. rosea | Rosavins + salidroside (graded) | Root | Per protocol | Identity-guaranteed extraction |
| Optisolv | Multiple | Compound-specific | Varies | Varies | Cyclodextrin + phospholipid |
FAQs
Why does the type of withanolide matter more than the total percentage?
Withanolide glycosides are more water-soluble and demonstrate significantly higher oral bioavailability than aglycones. A 2025 crossover study found glycoside-rich extracts delivered 226-fold higher systemic exposure per milligram than aglycone-dominant extracts at equivalent total withanolide doses.[1]
How can formulators verify rhodiola extract quality?
Request COAs that separately quantify rosavin and salidroside using validated chromatographic methods (UPLC). The clinical benchmark is 3% rosavins and 1% salidroside. Independent third-party verification is recommended, given that a 2026 analysis found label claim deviations of up to five-fold on the U.S. market.[2]
What excipient compatibility issues affect adaptogen stability?
Withanolides are sensitive to moisture above 10%, oxidation, heat, and pH extremes. Magnesium stearate can accelerate hydrolysis by raising local pH. Ethyl cellulose showed the lowest interaction with withanolides in compatibility testing.[10,11]
What bioavailability technologies are available for adaptogens?
Current options include phytosome technology (phospholipid complexation), cyclodextrin inclusion complexation, dual-coating cyclodextrin-phospholipid systems (Evanium Optisolv), microencapsulation, and nanofiber-based delivery. Selection depends on the active’s properties, the dosage form, and the regulatory pathway.
Do enhanced-delivery adaptogens require separate regulatory authorization?
Potentially. In the EU, novel delivery technologies may trigger novel food authorization. In the U.S., substantially different ingredient forms may require an NDI notification to the FDA. Evaluate on a product-by-product basis.[17]
What analytical methods should procurement teams require for adaptogen COAs?
For ashwagandha, request HPLC quantification of individual withanolides (not just total percentage), specifying glycoside vs. aglycone content. For rhodiola, require separate rosavin and salidroside quantification via UPLC. For reishi, require Megazyme K-YBGL for beta-glucan with separate alpha-glucan reporting, plus HPLC for ganoderic acid content. In all cases, the analytical method should be stated on the COA.[1,2,8]
Key Takeaways
Withanolide type, not total percentage, determines ashwagandha bioavailability: glycoside-rich extracts show up to 226-fold higher systemic exposure per milligram than aglycone-dominant extracts.
Commercial rhodiola supplements show rosavin levels ranging from 0.01% to 3.08%, with label deviations of up to five-fold, underscoring the need for compound-specific COA verification.
Withanolide stability is vulnerable to moisture above 10%, oxidation, and pH extremes, making excipient compatibility testing a non-negotiable formulation step.
Bioavailability platforms showcased at Vitafoods 2026 (phytosome, cyclodextrin-phospholipid dual coating, microencapsulation) offer formulators multiple approaches to address the inherent absorption limitations of adaptogen actives.
Low-dose, high-potency extracts (30-60 mg daily) now enable adaptogen delivery in gummies, dissolving strips, and functional beverages.
Sources
- Agarwal, R., et al., “Randomized, Double-Blind, Crossover Study Comparing the Bioavailability of 4 Ashwagandha Extracts in Healthy Adults Under Fasting Condition,” 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12337022/ (accessed May 2026).
- University of California, Irvine, “The quality and safety of Rhodiola rosea supplements on the U.S. market,” PLOS ONE, 2026. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0341070 (accessed May 2026).
- Panossian, A. and Wikman, G., “Effects of Adaptogens on the Central Nervous System,” Pharmaceuticals, 2010;3(1):188-224.
- NutraIngredients, “Top 5 ashwagandha formulation challenges and how to overcome them,” 2025. https://www.nutraingredients.com/News/Promotional-features/how-to-overcome-challenges-in-ashwagandha-formulation/ (accessed May 2026).
- Natural Remedies, “Ashwa.30, a Next-Gen Ashwagandha for Energy, Endurance and Stress Support,” GlobeNewswire, May 2025. https://www.globenewswire.com/news-release/2025/05/20/3084859/0/en/Natural-Remedies-Introduces-Ashwa-30-a-Next-Gen-Ashwagandha-for-Energy-Endurance-and-Stress-Support.html (accessed May 2026).
- Anghelescu, I.G., et al., “Stress management and the role of Rhodiola rosea,” International Journal of Psychiatry in Clinical Practice, 2018;22(4):242-252.
- NutritionInsight, “Nektium to spotlight stress relief, sleep support & endurance boosters at Vitafoods Europe 2026,” 2026. https://www.nutritioninsight.com/news/nektium-vitafoods-2026-botanicals.html (accessed May 2026).
- Scientific Reports, “Evaluation on quality consistency of Ganoderma lucidum dietary supplements,” 2017. https://www.nature.com/articles/s41598-017-06336-3 (accessed May 2026).
- Nammex, “Redefining Medicinal Mushrooms.” https://www.nammex.com/redefining-medicinal-mushrooms/ (accessed May 2026).
- Patwardhan, B., et al., “Physicochemical Stability and Biological Activity of Withania somnifera Extract,” Planta Medica, 2009. https://pubmed.ncbi.nlm.nih.gov/19844862/ (accessed May 2026).
- Drug-Excipient Interactions: Case Studies and Overview of Drug Degradation Pathways, American Journal of Analytical Chemistry, 2016;7:107-140.
- Nutraceutical Business Review, “Indena unveils advanced botanical solutions at Vitafoods 2026,” 2026. https://nutraceuticalbusinessreview.com/indena-unveils-advanced-botanical-solutions-for-enhanced-healthy (accessed May 2026).
- Nutraceutical Business Review, “EVANIUM raises 2.2 million seed round,” 2026. https://nutraceuticalbusinessreview.com/evanium-raises-2-2-million-seed-round-to-solve (accessed May 2026).
- “Cyclodextrin/PVP-Based Nanofibers with Rhodiola rosea Extract,” Polymers, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12388008/ (accessed May 2026).
- NutraIngredients, “Vitafoods Europe show floor preview: H-N,” April 2026. https://www.nutraingredients.com/Article/2026/04/30/vitafoods-show-floor-preview-h-p/ (accessed May 2026).
- Nutraceutical Business Review, “Laboratoire PYC to showcase adaptogen beverage platforms at Vitafoods Europe,” 2026. https://nutraceuticalbusinessreview.com/laboratoire-pyc-showcase-glp-1-support-adaptogen-vitafoods (accessed May 2026).
- Regulation (EU) 2015/2283 on novel foods. See also: FDA Guidance for Industry, “Dietary Supplements: New Dietary Ingredient Notifications and Related Issues.”
These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.
